A phase II trial was performed to evaluate the efficacy and safety of gefitinib in patients with persistent/recurrent endometrial cancer.
Gefitinib; endometrial cancer; epidermal growth factor receptor (EGFR); soluble EGFR; estrogen receptor; progesterone receptor
Copyright © Kimberly K. Leslie, Michael W. Sill, Edgar Fischer, Kathleen M. Darcy, Robet S. Mannel, Krishnansu S. Tewari, Parviz Hanjan, Jason A. Wilken, Andre T. Baron, Andrew K. Godwin, Russell J. Schilder, Meenakshi Singh, Nita J. Maihle, 2013.
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.
Leslie KK. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study*. Proc Obstet Gynecol. 2013 Nov 04;3(4):Article 5 [2 p.]. https://doi.org/10.17077/2154-4751.1226. Free full text article.